玻璃体腔内注射TA与IVR治疗CRVO继发ME的临床疗效对比观察

Compared Clinical Curative Effect of Intravitreal Injection TA and IVR in Treatment of CRVO Secondary ME

目的探讨玻璃体腔内注射曲安奈德（TA）与雷珠单抗（IVR）治疗视网膜中央静脉阻塞（CRVO）继发黄斑水肿（ME）的临床疗效差异。方法选择2013年1月-2014年10月我院眼科收治的CRVO继发ME患者75例共75眼,根据收治顺序分为TA组（n=38）和IVR组（n=37）,TA组给予玻璃体腔内注射TA治疗,IVR组给予玻璃体腔内注射IVR治疗。结果与治疗前相比两组治疗后各时间点CMT,P〈0.05,差异具有统计学意义,但两组相同时间点CMT比较,P〉0.05,差异具有统计学意义。结论玻璃体腔内注射TA与IVR均能降低CRVO继发ME患者CMT。

Objective To explore the comparison of the clinical efficacy between triamcinolone acetonide （TA） and Intravitreal ranibizumab （IVR） by vitreous cavity injection on patients with macular edema （ME） secondary to central retinal vein occlusion （CRVO）.MethodsRespectively selected 75 cases totally 75 eyes patients with ME secondary to CRVO from October 2013 to January 2013, were divided into TA group （n=38） and IVR （n=37） according to the order, patients in TA group were treated with TA by vitreous cavity injection, while patients in IVR group were treated with IVR by vitreous cavity injection. Results Compared with before treatment, the CMT at each time point after treatment in the two groups,P〈0.05, had difference statistically significance, but compared the two groups at the same point,P〉0.05, had no difference statistically signiifcance.Conclusion TA and IVR by vitreous cavity injection can reduce CMT on patients with ME secondary to CRVO.